Pharmaceutical Ingredients

Impurities

Intermediates

Metabolites



Anti-Infective Agents

Anti-Cancer Agents

Anti-Diabetic Agents

Cardiovascular Agents

Central Nervous System

Gastrointestinal Agents

Immunosuppressive Agents

Pheromone Ingredients

Respiratory Agents



New Products:

      Acebrophylline

      Daptomycin

      Ecabet Sodium

      Echinocandin B

      Epothilone A & B

      Everolimus

      Geldanamycin

      Levocloperastine

      Mupirocin

      Orlistat

      Pentostatin

      Pimecrolimus

      Pneumocandin A0

      Pneumocandin B0

      Pristinamycin IA & IIA

      Propiverine HCl

      Rebeccamycin

      Teicoplanin

      Temsirolimus

      Vancomycin HCl

      Voglibose

      Zotarolimus

      ......

Links


RESEARCH AND DEVELOPMENT

Active Pharmaceutical Ingredients (API's) can be produced by chemical synthesis, microbial fermentation or isolation from natural sources. Most API's are small organic molecules that are usually manufactured by using synthetic process, however, chemical processing has created major concerns for environmental protection. To some extent, it's not economical (or not possible) to produce many small or large organic molecules or biochemicals using conventional chemical process. To this end, biotechnology including microbial fermentation has been playing more and more important role in the fine chemical and pharmaceutical industry.

Most fermentation-based API's are secondary metabolites produced by micro-organisms such as fungi and actinomycetes. The micro-organisms are capable of converting inexpensive carbon sources (starch, glucose, sucrose, etc.) and nitrogen sources (soybean flour, cotton-seed flour, peptone, etc.) into highly valuable API's or key intermediates (such as amino acids, vitamines, antibiotics) in liquid or solid media under certain growth conditions (nutrients, temperature, PH, oxygen supply).

We are not only involved in development of synthetic processes, but also paying attention to process development and optimization for production of API's and related products of small molecules using submerged fermentation technology. Current projects include process research and development for production of immuno-suppressants (Tacrolimus / FK-506, Rapamycin / Sirolimus, Everolimus, Zotarolimus, Ascomycin / FK-520, Pimecrolimus, Cyclosporine, Mycophenolic Acid and Mycophenolate Mofetil), antibiotics (Vancomycin HCl, Daptomycin, Pristinamycin, Teicoplanin), anticancer agents (Epothilone A & B, Pentostatin) and antidiabetic agents (Acarbose, Miglitol, Voglibose), etc.


Copyright  © 2005  All Rights Reserved.

MOLCAN CORPORATION, Canada, Tel. 905-731-5537, Fax 905-248-3843, E-Mail: contact@molcan.com